|
|
|
Content :
A world-class pharmaceutical manufacturer
Sanofi India Limited was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited and Hoechst Marion Roussel Limited.
Sanofi, one of the world's leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange (Security Code: 500674) and the National Stock Exchange (Security Code: AVENTIS EQ).
SANOFI INDIA LIMITED
Shareholding Pattern (as on 31st March 2013)
Shareholding Pattern (as on 31st March 2013) | N° of shareholders | N° of shares held | % of shares held |
|---|
| a) Foreign Promoters (Hoechst GmbH/ Sanofi) | 2 | 13,909,587 | 60.40 |
|---|
| b) Mutual Funds/ UTI | 33 | 2,456,618 | 10.67 |
|---|
| c) Financial Institutions / Banks | 13 | 20,725 | 0.09 |
|---|
| d) Insurance Companies | 3 | 537,401 | 2.33 |
|---|
| e) Foreign Institutional Investors | 25 | 3,143,542 | 13.65 |
|---|
| f) Bodies Corporate | 229 | 1,554,623 | 6.75 |
|---|
| g) Trusts | 5 | 476 | 0.00 |
|---|
| h) Clearing Members | 54 | 5,179 | 0.02 |
|---|
| i) Hindu Undivided Family | 34 | 7,569 | 0.03 |
|---|
| j) Individuals holding upto Rs.1 lakh in nominal capital | 12,941 | 1,081,343 | 4.70 |
|---|
| k) Individuals holding more than Rs.1 lakh in nominal capital | 4 | 114,740 | 0.50 |
|---|
| l) Non-Resident Indians (with repatriation benefits) | 97 | 5,550 | 0.02 |
|---|
| m) Non-Resident Indians (without repatriation benefits) | 81 | 193,189 | 0.84 |
|---|
| n) Director / Relatives | 1 | 80 | 0.00 |
|---|
| Total | 13,522 | 23,030,622 | 100.00 |
|---|
Updated April 15, 2013
|
Module :
Corporate information
Medical Information / Pharmacovigilance
A key activity of Sanofi is to provide updated medical information on its products, to healthcare professionals, which is in compliance with Indian regulations. All consumers or patients are advised to contact their doctor or healthcare professional for advice on medicines or any health matters.
For medical information, contact:
medinfo.india@sanofi.com
Sanofi also ensures continuous monitoring and management of the safety profile of all its products through its drug safety data collection worldwide, as pharmacovigilance remains a key activity in the assessment of the therapeutic value of products.
For information on Drug Safety and Reporting of Adverse Events, please contact:
Dr. Rajani Rokade, Affiliate Pharmacovigilance Head
Tel.: +91-22-28278055
Fax: +91-22-28208667 /
+91-22-28278044
Email:
pv.india@sanofi.com
|
|
